EMA Authorised: Faslodex (fulvestrant) — AstraZeneca AB

View source ↗

Summary

The EMA authorised Faslodex (fulvestrant) for breast cancer under the marketing authorisation holder AstraZeneca AB, decision dated 14 May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: AstraZeneca AB. Decision date: 14/05/2025